| Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer JB Vermorken, E Remenar, C Van Herpen, T Gorlia, R Mesia, M Degardin, ... New England Journal of Medicine 357 (17), 1695-1704, 2007 | 2126 | 2007 |
| Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory … D Strumberg, H Richly, RA Hilger, N Schleucher, S Korfee, M Tewes, ... Journal of clinical oncology 23 (5), 965-972, 2005 | 1067 | 2005 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 954 | 2018 |
| Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ... Annals of Oncology 30 (3), 397-404, 2019 | 701 | 2019 |
| Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer HJ Burstein, Y Sun, LY Dirix, Z Jiang, R Paridaens, AR Tan, A Awada, ... J Clin Oncol 28 (8), 1301-1307, 2010 | 631 | 2010 |
| Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double … J Baselga, SA Im, H Iwata, J Cortés, M De Laurentiis, Z Jiang, CL Arteaga, ... The Lancet Oncology 18 (7), 904-916, 2017 | 527 | 2017 |
| Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an … PA Kaufman, A Awada, C Twelves, L Yelle, EA Perez, G Velikova, ... Journal of clinical oncology 33 (6), 594, 2015 | 491 | 2015 |
| Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors D Strumberg, JW Clark, A Awada, MJ Moore, H Richly, A Hendlisz, ... The oncologist 12 (4), 426-437, 2007 | 480 | 2007 |
| Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer TA Traina, K Miller, DA Yardley, J Eakle, LS Schwartzberg, ... Journal of clinical oncology 36 (9), 884, 2018 | 478 | 2018 |
| Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized … R Paridaens, L Biganzoli, P Bruning, JGM Klijn, T Gamucci, S Houston, ... Journal of clinical oncology 18 (4), 724-724, 2000 | 468 | 2000 |
| MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer S Johnston, M Martin, A Di Leo, SA Im, A Awada, T Forrester, M Frenzel, ... NPJ breast cancer 5 (1), 5, 2019 | 464 | 2019 |
| Randomized phase II study of the anti–epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple … J Baselga, P Gómez, R Greil, S Braga, MA Climent, AM Wardley, ... Journal of clinical oncology 31 (20), 2586-2592, 2013 | 442 | 2013 |
| Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial S Leboulleux, L Bastholt, T Krause, C de la Fouchardiere, J Tennvall, ... The lancet oncology 13 (9), 897-905, 2012 | 426 | 2012 |
| Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours A Awada, A Hendlisz, T Gil, S Bartholomeus, M Mano, D de Valeriola, ... British journal of cancer 92 (10), 1855-1861, 2005 | 407 | 2005 |
| Side effects of approved molecular targeted therapies in solid cancers C Widakowich, G de Castro Jr, E De Azambuja, P Dinh, A Awada The oncologist 12 (12), 1443-1455, 2007 | 402 | 2007 |
| Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR … G Gebhart, LE Lamberts, Z Wimana, C Garcia, P Emonts, L Ameye, ... Annals of oncology 27 (4), 619-624, 2016 | 347 | 2016 |
| Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial J Trigo, V Subbiah, B Besse, V Moreno, R López, MA Sala, S Peters, ... The lancet oncology 21 (5), 645-654, 2020 | 332 | 2020 |
| Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial A Awada, R Colomer, K Inoue, I Bondarenko, RA Badwe, G Demetriou, ... JAMA oncology 2 (12), 1557-1564, 2016 | 316 | 2016 |
| Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane … J Cortes, L Vahdat, JL Blum, C Twelves, M Campone, H Roché, ... Journal of Clinical Oncology 28 (25), 3922-3928, 2010 | 274 | 2010 |
| Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer F Rothé, JF Laes, D Lambrechts, D Smeets, D Vincent, M Maetens, ... Annals of oncology 25 (10), 1959-1965, 2014 | 272 | 2014 |
